KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elanco Animal Health (ELAN) Capital Expenditures (2017 - 2025)

Historic Capital Expenditures for Elanco Animal Health (ELAN) over the last 9 years, with Q3 2025 value amounting to $92.0 million.

  • Elanco Animal Health's Capital Expenditures rose 11904.76% to $92.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $261.0 million, marking a year-over-year increase of 8510.64%. This contributed to the annual value of $147.0 million for FY2024, which is 500.0% up from last year.
  • Elanco Animal Health's Capital Expenditures amounted to $92.0 million in Q3 2025, which was up 11904.76% from $57.0 million recorded in Q2 2025.
  • In the past 5 years, Elanco Animal Health's Capital Expenditures ranged from a high of $99.0 million in Q4 2021 and a low of $17.0 million during Q2 2021
  • Moreover, its 5-year median value for Capital Expenditures was $39.0 million (2022), whereas its average is $43.7 million.
  • The largest annual percentage gain for Elanco Animal Health's Capital Expenditures in the last 5 years was 25357.14% (2021), contrasted with its biggest fall of 7159.09% (2021).
  • Over the past 5 years, Elanco Animal Health's Capital Expenditures (Quarter) stood at $99.0 million in 2021, then decreased by 22.22% to $77.0 million in 2022, then plummeted by 46.75% to $41.0 million in 2023, then grew by 14.63% to $47.0 million in 2024, then skyrocketed by 95.74% to $92.0 million in 2025.
  • Its Capital Expenditures was $92.0 million in Q3 2025, compared to $57.0 million in Q2 2025 and $65.0 million in Q1 2025.